A citation-based method for searching scientific literature

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
Vera A Bittner, Michael Szarek, Philip E Aylward, Deepak L Bhatt, Rafael Diaz, Jay M Edelberg, Zlatko Fras, Shaun G Goodman, Sigrun Halvorsen, Corinne Hanotin, Robert A Harrington, J Wouter Jukema, Virginie Loizeau, Patrick M Moriarty, Angèle Moryusef, Robert Pordy, Matthew T Roe, Peter Sinnaeve, Sotirios Tsimikas, Robert Vogel, Harvey D White, Doron Zahger, Andreas M Zeiher, Ph Gabriel Steg, Gregory G Schwartz. J Am Coll Cardiol 2020
Times Cited: 150



Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population.
Pia R Kamstrup, Anne Tybjærg-Hansen, Børge G Nordestgaard. J Am Coll Cardiol 2014
Times Cited: 301




List of shared articles



Times cited

Lipoprotein(a).
Florian Kronenberg. Handb Exp Pharmacol 2022
1

Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview.
Ioannis Parthymos, Michael S Kostapanos, Dimitri P Mikhailidis, Matilda Florentin. Eur J Prev Cardiol 2022
2

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.
Gissette Reyes-Soffer, Henry N Ginsberg, Lars Berglund, P Barton Duell, Sean P Heffron, Pia R Kamstrup, Donald M Lloyd-Jones, Santica M Marcovina, Calvin Yeang, Marlys L Koschinsky. Arterioscler Thromb Vasc Biol 2022
14

Therapeutic RNA-silencing oligonucleotides in metabolic diseases.
Algera Goga, Markus Stoffel. Nat Rev Drug Discov 2022
0

Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease.
David A Rider, Mona Eisermann, Kathrin Löffler, Manuela Aleku, Daniel I Swerdlow, Sibylle Dames, Judith Hauptmann, Eliot Morrison, Marie Wikström Lindholm, Steffen Schubert,[...]. Atherosclerosis 2022
1

Association Between Lipoprotein(a) and Calcific Aortic Valve Disease: A Systematic Review and Meta-Analysis.
Qiyu Liu, Yanqiao Yu, Ruixi Xi, Jingen Li, Runmin Lai, Tongxin Wang, Yixuan Fan, Zihao Zhang, Hao Xu, Jianqing Ju. Front Cardiovasc Med 2022
0

Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care.
Wann Jia Loh, Dick C Chan, Pedro Mata, Gerald F Watts. Front Genet 2022
0

Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.
Freddy Duarte Lau, Robert P Giugliano. JAMA Cardiol 2022
0

Considerations for routinely testing for high Lp(a).
Nick S Nurmohamed, Patrick M Moriarty, Erik S G Stroes. Curr Opin Lipidol 2022
0

Lipoprotein(a): Expanding our knowledge of aortic valve narrowing.
Amer Youssef, Justin R Clark, Marlys L Koschinsky, Michael B Boffa. Trends Cardiovasc Med 2021
9

Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.
Ron C Hoogeveen, Christie M Ballantyne. Clin Chem 2021
24

Recent Updates of Lipoprotein(a) and Cardiovascular Disease.
Taili Liu, Won-Sik Yoon, Sang-Rok Lee. Chonnam Med J 2021
4

Drugs for Prevention and Treatment of Aortic Stenosis: How Close Are We?
Mehdi Afshar, Shayan Yazdan-Ashoori, James C Engert, George Thanassoulis. Can J Cardiol 2021
3

The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Marcio H Miname, Viviane Z Rocha, Raul D Santos. Curr Atheroscler Rep 2021
6

Lipoprotein (a): Recent Updates on a Unique Lipoprotein.
Anum Saeed, Sina Kinoush, Salim S Virani. Curr Atheroscler Rep 2021
4

Lipoprotein (a): When to Measure and How to Treat?
David Rhainds, Mathieu R Brodeur, Jean-Claude Tardif. Curr Atheroscler Rep 2021
3

Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis.
Chih-Kuo Lee, Che-Wei Liao, Shih-Wei Meng, Wei-Kai Wu, Jiun-Yang Chiang, Ming-Shiang Wu. Biomedicines 2021
5


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy